نتائج البحث - Panagiotis Malandrakis

  • يعرض 1 - 14 نتائج من 14
تنقيح النتائج
  1. 1
    Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

    Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies حسب Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Efstathios Kastritis, Evangelos Terpos, Meletios Α. Dimopoulos, Maria Gavriatopoulou

    منشور في 2025
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials

    Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials حسب Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios Α. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou

    منشور في 2025
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

    Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 حسب Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, Zoi Evangelakou, Maria Gavriatopoulou, Maria S. Manola, Panagiotis Malandrakis, Despoina D. Gianniou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios Α. Dimopoulos

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

    Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome حسب Konstantinos Soureas, Panagiotis Malandrakis, M. Papadimitriou, Christos Minopoulos, Ioannis Ntanasis-Stathopoulos, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Α. Dimopoulos, Andreas Scorilas, Margaritis Avgeris, Evangelos Terpos

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

    Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy حسب Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Eleni‐Dimitra Papanagnou, Magdalini Migkou, Nikolaos Kanellias, Efstathios Kastritis, Ioannis P. Trougakos, Meletios Α. Dimopoulos

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    <scp>XBB</scp>.1.5 neutralizing antibodies upon bivalent <scp>COVID</scp>‐19 vaccination are similar to <scp>XBB</scp> but lower than <scp>BQ</scp>.1.1

    <scp>XBB</scp>.1.5 neutralizing antibodies upon bivalent <scp>COVID</scp>‐19 vaccination are similar to <scp>XBB</scp> but lower than <scp>BQ</scp>.1.1 حسب Santhi Devasundaram, Evangelos Terpos, Margherita Rosati, Ioannis Ntanasis‐Stathopoulos, Jenifer Bear, Robert Burns, Stamatia Skourti, Panagiotis Malandrakis, Ioannis P. Trougakos, Meletios Α. Dimopoulos, George N. Pavlakis, Barbara K. Felber

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

    Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine حسب Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Αlexandros Briasoulis, Sentiljana Gumeni, Ioannis Ntanasis‐Stathopoulos, Aimilia D. Sklirou, Panagiotis Malandrakis, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Ioannis P. Trougakos, Meletios Α. Dimopoulos

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study <scp>DARIA</scp>

    Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study <scp>DARIA</... حسب Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Panagiotis Malandrakis, Evgenia Verrou, Stavros Golfinopoulos, Magdalini Migkou, Kyriaki Manousou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios Α. Dimopoulos

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study

    Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study حسب Maria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Ioannis P. Trougakos, Meletios Α. Dimopoulos

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Small <scp>RNA</scp>‐seq and clinical evaluation of <scp>tRNA</scp>‐derived fragments in multiple myeloma: Loss of mitochondrial <scp>i‐tRF<sup>HisGTG</sup></scp> results in patients' poor treatment outcome

    Small <scp>RNA</scp>‐seq and clinical evaluation of <scp>tRNA</scp>‐derived fragments in multiple myeloma: Loss of mitochondrial <scp>i‐tRF<sup>HisGTG</sup></scp> results in patien... حسب Konstantinos Soureas, M. Papadimitriou, Panagiotis Malandrakis, Αριστέα-Μαρία Παπανώτα, Panagiotis G. Adamopoulos, Ioannis Ntanasis‐Stathopoulos, Christine‐Ivy Liacos, Maria Gavriatopoulou, Diamantis C. Sideris, Efstathios Kastritis, Meletios Α. Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice

    Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice حسب Ioannis Ntanasis‐Stathopoulos, Vassilis Koutoulidis, Panagiotis Malandrakis, Despina Fotiou, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Nikolaos Kanellias, Foteini Theodorakakou, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis, Evangelos Terpos, Meletios Α. Dimopoulos, Lia A. Moulopoulos, Maria Gavriatopoulou

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring

    Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring حسب Efstathios Kastritis, Eirini Solia, Panagiotis Malandrakis, Foteini Theodorakakou, Ioannis Ntanasis‐Stathopoulos, Nikolaos Kanellias, Despoina Fotiou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Vassiliki Spiliopoulou, Nikoletta‐Aikaterini Kokkali, Asimina Papanikolaou, Stavroula Giannouli, Maria Gavriatopoulou, Evangelos Terpos, M.A.C. Dimopoulos

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

    The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment حسب Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Eleni‐Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios Α. Dimopoulos

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

    Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy حسب Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, Panagiotis Malandrakis, Aimilia D. Sklirou, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Μαρία Ρούσσου, Despina Fotiou, Harry Alexopoulos, Foteini Theodorakakou, Efstathios Kastritis, Vassiliki A. Iconomidou, Ioannis P. Trougakos, Meletios Α. Dimopoulos, Evangelos Terpos

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: